Cancer research

Global Humanized Mice Model Market to 2025 by Service, Type, Immune Checkpoints, Application, End-user, and Region

Thursday, January 21, 2021 - 12:45pm

The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.

Key Points: 
  • The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.
  • In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market.
  • The Global Humanized Mice Model Market is segmented based on service, type, immune checkpoints, application, end-user, and region.
  • Based on type, the market is fragmented into cell line transplantation model, patient derived xenografts, genetically engineered mouse model and others.

AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer Research

Tuesday, January 19, 2021 - 2:39pm

Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.

Key Points: 
  • Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.
  • These grants are part of OIFs impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation.
  • Receipt of this AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grant represents a critical milestone in my development as an independent scientist, said Eil.
  • Founded in 1907, the American Association for Cancer Research (AACR) is the worlds first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer.

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Wednesday, January 13, 2021 - 11:01pm

The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.

Key Points: 
  • The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.
  • Based on the data from these trials, ImmunityBio is conducting a pivotal, three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.
  • A randomized Phase 2 study (QUILT 88, Cohorts A and B) for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.
  • On the basis of our initial studies, we initiated our QUILT 88 randomized trials in metastatic pancreatic cancer and are pleased to present today those findings, including Cohort C survival rates.

Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute

Tuesday, January 12, 2021 - 9:05pm

CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI).

Key Points: 
  • CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI).
  • The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years.
  • "This contract for Brooks to provide whole exome sequencing to the National Cancer Institute demonstrates the outstanding reputation of GENEWIZ in the cancer research community," commentedSteve Schwartz, president and CEO of Brooks Automation.
  • The Center for Cancer Genomics coordinates research teams across the United States and Canada to produce rich cancer genomic and clinical datasets for the cancer research community.

Debbie's Dream Foundation: Curing Stomach Cancer Announces Winners of the 2020 Scholarship Essay Contest

Friday, January 8, 2021 - 1:31pm

PLANTATION, Fla., Jan. 8, 2021 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2020 DDF Scholarship Essay Contest.

Key Points: 
  • PLANTATION, Fla., Jan. 8, 2021 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2020 DDF Scholarship Essay Contest.
  • Justyn Boumah, 5, from Las Vegas, won $100 in the elementary school division for his essay on the dream he holds for finding a cure for stomach cancer.
  • Each year, DDF's essay contest is open to children between the ages of 5 to 18 across the United States.
  • Debbie is considered a pioneer by many for bringing awareness to stomach cancer patients' plight and the lack of federal funding for stomach cancer research.

Stupid Strong Charitable Foundation Pledges $250,000 to Support Gastric Cancer Research at MD Anderson Cancer Center

Wednesday, December 23, 2020 - 11:00am

FORT-WORTH, Texas, Dec. 23, 2020 /PRNewswire/ --Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support cutting-edge research in gastric cancer led by Jaffer Ajani, M.D., professor of Gastrointestinal Medical Oncology.

Key Points: 
  • FORT-WORTH, Texas, Dec. 23, 2020 /PRNewswire/ --Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support cutting-edge research in gastric cancer led by Jaffer Ajani, M.D., professor of Gastrointestinal Medical Oncology.
  • The Cless Family Foundation was touched to make a gift after reading an article in MD Anderson's Promise magazine highlighting Stupid Strong Foundation's 2019 donation to support gastric cancer research.
  • The knowledge gained by the research team will allow MD Anderson to target the unique metabolism and pathways of gastric cancer.
  • To date, Stupid Strong has granted over $775,000 to institutions around the globe for gastric cancer research and community support.

Budget Passed By Congress Includes Increase In Federal Funding For Cancer Research

Tuesday, December 22, 2020 - 3:43pm

In response to the advocacy efforts of the Pancreatic Cancer Action Network (PanCAN), the spending package includes $15 million for the Department of Defense's (DoD) dedicated Pancreatic Cancer Research Program, more than doubling last year's inaugural investment.

Key Points: 
  • In response to the advocacy efforts of the Pancreatic Cancer Action Network (PanCAN), the spending package includes $15 million for the Department of Defense's (DoD) dedicated Pancreatic Cancer Research Program, more than doubling last year's inaugural investment.
  • In addition, the package includes an overall increase in the nation's investment in biomedical research funding of $42.9 billion to the National Institutes of Health (NIH) and $6.56 billion to the National Cancer Institute (NCI).
  • Currently, more than 80 percent of research funding for pancreatic cancer comes from the federal government.
  • We are so grateful to our champions in Congress who work side-by-side PanCAN advocates to prioritize pancreatic cancer research funding."

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

Tuesday, December 22, 2020 - 1:00pm

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies.
  • The antiviral and anti-inflammatory activity of ADX-1612 demonstrated in COVID-19 models may be applicable to viral diseases generally, stated Emanuel Wyler, Ph.D., Research Scientist at MDC.
  • In May 2020, Dr. Wyler and colleagues identified HSP90 as a key antiviral target against SARS-CoV-21 and have confirmed the antiviral activity of ADX-1612, a potent HSP90 inhibitor, reported by Aldeyra earlier this year.
  • Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases.

Sarah Cannon Promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research

Thursday, December 17, 2020 - 9:18pm

Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research.

Key Points: 
  • Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research.
  • Since joining Sarah Cannon, Dr. Johnsons contributions to research have helped transform the treatment options available to patients facing lung cancer, said David Spigel , MD, Chief Scientific Officer, Sarah Cannon.
  • Since joining Sarah Cannon in 2014, Dr. Johnson has served as the Associate Director of Lung Cancer Research at Sarah Cannon Research Institute, supporting the growth of early phase compound thoracic malignancies.
  • Sarah Cannon Research Institute is the research arm of HCA Healthcares global cancer institute, Sarah Cannon.

New Research Suggests Multi-Cancer Early Detection Blood Test Could Reduce Late-Stage Cancer Diagnoses by More Than Half

Wednesday, December 16, 2020 - 8:18pm

Published in Cancer Epidemiology, Biomarkers & Prevention , a journal of the American Association for Cancer Research, the analysis used epidemiologic modeling to estimate the potential impact of adding an annual multi-cancer early detection blood test, such as GRAILs Galleri, to standard of care cancer screenings.

Key Points: 
  • Published in Cancer Epidemiology, Biomarkers & Prevention , a journal of the American Association for Cancer Research, the analysis used epidemiologic modeling to estimate the potential impact of adding an annual multi-cancer early detection blood test, such as GRAILs Galleri, to standard of care cancer screenings.
  • The model estimates a potential reduction in late-stage (stage III and IV) cancer diagnoses by more than half in the U.S. population, aged 50-79.
  • Cancers responsible for nearly 71% of cancer deaths have no recommended early detection screening.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.